Table 2.
Blood cytokine data of 40 men assigned to either placebo or MSM for four weeks.
| Baseline 1 | Baseline 2 | At 0 hrs | After 24 hrs | After 48 hrs | After 72 hrs | |
|---|---|---|---|---|---|---|
| IL-6 (pg·mL−1) Placebo |
10.3 ± 5.0 | 18.3 ± 7.2 | 16.8 ± 6.9 | 15.4 ± 6.3 | 19.1 ± 9.5 | 17.6 ± 11.2 |
| IL-6 (pg·mL−1) MSM |
14.4 ± 4.4 | 11.6 ± 2.9 | 16.0 ± 3.1 | 17.9 ± 4.5 | 13.7 ± 3.5 | 13.9 ± 3.5 |
|
| ||||||
| IL-8 (pg·mL−1) Placebo |
32.8 ± 10.0 | 39.7 ± 14.6 | 46.4 ± 15.9 | 30.7 ± 12.3 | 31.2 ± 13.7 | 41.3 ± 14.9 |
| IL-8 (pg·mL−1) MSM |
28.3 ± 6.1 | 24.0 ± 5.4 | 37.6 ± 8.3 | 30.2 ± 5.6 | 24.5 ± 4.4 | 29.6 ± 7.2 |
|
| ||||||
| IL-10 (pg·mL−1)∗
Placebo |
6.1 ± 1.6 | 6.5 ± 1.7 | 5.7 ± 1.2 | 6.2 ± 1.5 | 4.8 ± 1.1 | 6.0 ± 1.5 |
| IL-10 (pg·mL−1) MSM |
22.6 ± 8.1 | 17.7 ± 6.6 | 26.8 ± 9.4 | 19.3 ± 6.8 | 18.4 ± 7.0 | 18.1 ± 6.9 |
|
| ||||||
| IL-17 (pg·mL−1)∗
Placebo |
54.3 ± 15.3 | 65.7 ± 22.2 | 72.9 ± 26.3 | 42.6 ± 13.6 | 47.2 ± 16.8 | 69.5 ± 25.1 |
| IL-17 (pg·mL−1) MSM |
27.3 ± 8.4 | 24.4 ± 7.2 | 33.5 ± 8.2 | 30.1 ± 7.7 | 22.8 ± 5.0 | 28.5 ± 6.9 |
|
| ||||||
| IL-1β (pg·mL−1)∗
Placebo |
3.7 ± 1.1 | 2.7 ± 0.8 | 2.8 ± 0.8 | 2.8 ± 0.7 | 3.3 ± 1.1 | 3.3 ± 1.0 |
| IL-1β (pg·mL−1) MSM |
10.8 ± 3.2 | 10.4 ± 3.2 | 15.5 ± 4.6 | 18.7 ± 7.6 | 15.8 ± 5.8 | 12.0 ± 3.4 |
|
| ||||||
| TNF-α (pg·mL−1)∗
Placebo |
3.3 ± 0.8 | 2.1 ± 0.4 | 3.4 ± 0.6 | 2.3 ± 0.7 | 2.3 ± 0.6 | 2.7 ± 0.8 |
| TNF-α (pg·mL−1) MSM |
4.8 ± 0.6 | 3.8 ± 0.5 | 5.9 ± 0.6 | 4.7 ± 0.7 | 4.1 ± 0.5 | 4.6 ± 0.7 |
Values are mean ± SEM.
∗Condition effect for IL-10 (p = 0.001), IL-17 (p = 0.0005), IL-1β (p = 0.0003), and TNF-α (p < 0.0001).
No other statistically significant effects noted (p > 0.05).